« Back to Exclusive Articles

Diet and Dementia: Evidence for Protective Effects of Diet and Nutrition

This content is restricted to members.

To view our premium content, sign up for a membership:

Register New Account

Username

First Name

Last Name

Password

Password Again

Choose your membership level

Monthly Membership - €24.99 - 1 Month
Full Education Hub access: the weekly Study Deepdive, bi-monthly video Research Lectures, Exclusive Articles, and the full backcatalog of Deepdives in downloadable pdf format.
Annual Membership - €249.99 - 1 Year
Access to all the Education Hub content, at a reduced annual rate.

Discount Code - Valid - Invalid

Choose Your Payment Method

Credit / Debit Card PayPal

I agree to the privacy policy

‹ Back to Exclusive Articles

References

1. Cummings J, Morstorf T, Zhong K. Alzheimer’s disease drug-development pipeline: few candidates, frequent failures. Alzheimer’s Research & Therapy. 2014;6(4):37.

2. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi H. Forecasting the global burden of Alzheimer’s disease. Alzheimer’s & Dementia. 2007;3(3):186-191.

3. Chu C, Tseng P, Stubbs B, Chen T, Tang C, Li D et al. Use of statins and the risk of dementia and mild cognitive impairment: A systematic review and meta-analysis. Scientific Reports. 2018;8(1).

4. Barberger-Gateau P, Letenneur L, Deschamps V, Pérès K, Dartigues J, Renaud S. Fish, meat, and risk of dementia: cohort study. BMJ. 2002;325(7370):932-933.

5. Kalmijn S, van Boxtel M, Ocke M, Verschuren W, Kromhout D, Launer L. Dietary intake of fatty acids and fish in relation to cognitive performance at middle age. Neurology. 2004;62(2):275-280.

6. Morris M, Evans D, Tangney C, Bienias J, Wilson R. Fish Consumption and Cognitive Decline With Age in a Large Community Study. Archives of Neurology. 2005;62(12):1849.

7. Morris M, Evans D, Bienias J, Tangney C, Bennett D, Wilson R et al. Consumption of Fish and n-3 Fatty Acids and Risk of Incident Alzheimer Disease. Archives of Neurology. 2003;60(7):940.

8. Tan Z, Harris W, Beiser A, Au R, Himali J, Debette S et al. Red blood cell omega-3 fatty acid levels and markers of accelerated brain aging. Neurology. 2012;78(9):658-664.

9. Samieri C, Maillard P, Crivello F, Proust-Lima C, Peuchant E, Helmer C et al. Plasma long-chain omega-3 fatty acids and atrophy of the medial temporal lobe. Neurology. 2012;79(7):642-650.

10. Samieri C, Féart C, Letenneur L, Dartigues J, Pérès K, Auriacombe S et al. Low plasma eicosapentaenoic acid and depressive symptomatology are independent predictors of dementia risk. The American Journal of Clinical Nutrition. 2008;88(3):714-721.

11. Morris M, Brockman J, Schneider J, Wang Y, Bennett D, Tangney C et al. Association of Seafood Consumption, Brain Mercury Level, and APOE ε4 Status With Brain Neuropathology in Older Adults. JAMA. 2016;315(5):489.

12. Cunnane S, Chouinard-Watkins R, Castellano C, Barberger-Gateau P. Docosahexaenoic acid homeostasis, brain aging and Alzheimer’s disease: Can we reconcile the evidence?. Prostaglandins, Leukotrienes and Essential Fatty Acids. 2013;88(1):61-70.

13. Dangour A, Allen E, Elbourne D, Fasey N, Fletcher A, Hardy P et al. Effect of 2-y n−3 long-chain polyunsaturated fatty acid supplementation on cognitive function in older people: a randomized, double-blind, controlled trial. The American Journal of Clinical Nutrition. 2010;91(6):1725-1732.

14. Quinn J, Raman R, Thomas R, Yurko-Mauro K, Nelson E, Van Dyck C et al. Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease. JAMA. 2010;304(17):1903.

15. Yurko-Mauro K, McCarthy D, Rom D, Nelson E, Ryan A, Blackwell A et al. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimer’s & Dementia. 2010;6(6):456-464.

16. Johnson E, Mcdonald K, Caldarella S, Chung H, Troen A, Snodderly D. Cognitive findings of an exploratory trial of docosahexaenoic acid and lutein supplementation in older women. Nutritional Neuroscience. 2008;11(2):75-83.

17. Sublette M, Ellis S, Geant A, Mann J. Meta-Analysis of the Effects of Eicosapentaenoic Acid (EPA) in Clinical Trials in Depression. The Journal of Clinical Psychiatry. 2011;72(12):1577-1584.

18. Serhan C, Arita M, Hong S, Gotlinger K. Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their endogenous aspirin-triggered epimers. Lipids. 2004;39(11):1125-1132.

19. Fontani G, Corradeschi F, Felici A, Alfatti F, Migliorini S, Lodi L. Cognitive and physiological effects of Omega-3 polyunsaturated fatty acid supplementation in healthy subjects. European Journal of Clinical Investigation. 2005;35(11):691-699.

20. Dyall S. Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA. Frontiers in Aging Neuroscience. 2015;7.

21. Sahlin C, Pettersson F, Nilsson L, Lannfelt L, Johansson A. Docosahexaenoic acid stimulates non-amyloidogenic APP processing resulting in reduced Aβ levels in cellular models of Alzheimer’s disease. European Journal of Neuroscience. 2007;26(4):882-889.

22. Green K, Martinez-Coria H, Khashwji H, Hall E, Yurko-Mauro K, Ellis L et al. Dietary Docosahexaenoic Acid and Docosapentaenoic Acid Ameliorate Amyloid- and Tau Pathology via a Mechanism Involving Presenilin 1 Levels. Journal of Neuroscience. 2007;27(16):4385-4395.

23. Oksman M, Iivonen H, Hogyes E, Amtul Z, Penke B, Leenders I et al. Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-amyloid accumulation in APP/PS1 transgenic mice. Neurobiology of Disease. 2006;23(3):563-572.

24. Goodenowe D, Cook L, Liu J, Lu Y, Jayasinghe D, Ahiahonu P et al. Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer’s disease and dementia. Journal of Lipid Research. 2007;48(11):2485-2498.

25. Wood P. Lipidomics of Alzheimer’s disease: current status. Alzheimer’s Research & Therapy. 2012;4(1):5.

26. Igarashi M, Ma K, Gao F, Kim H, Rapoport S, Rao J. Disturbed Choline Plasmalogen and Phospholipid Fatty Acid Concentrations in Alzheimer’s Disease Prefrontal Cortex. Journal of Alzheimer’s Disease. 2011;24(3):507-517.

27. Morris M, Evans D, Tangney C, Bienias J, Wilson R, Aggarwal N et al. Relation of the tocopherol forms to incident Alzheimer disease and to cognitive change. The American Journal of Clinical Nutrition. 2005;81(2):508-514.

28. Engelhart M, Geerlings M, Ruitenberg A, van Swieten J, Hofman A, Witteman J et al. Dietary Intake of Antioxidants and Risk of Alzheimer Disease. JAMA. 2002;287(24):3223.

29. Mangialasche F, Kivipelto M, Mecocci P, Rizzuto D, Palmer K, Winblad B et al. High Plasma Levels of Vitamin E Forms and Reduced Alzheimer’s Disease Risk in Advanced Age. Journal of Alzheimer’s Disease. 2010;20(4):1029-1037.

30. Luchsinger J, Tang M, Shea S, Mayeux R. Antioxidant Vitamin Intake and Risk of Alzheimer Disease. Archives of Neurology. 2003;60(2):203.

31. Morris M, Schneider J, Li H, Tangney C, Nag S, Bennett D et al. Brain tocopherols related to Alzheimer’s disease neuropathology in humans. Alzheimer’s & Dementia. 2014;11(1):32-39.

32. Hooper L, Ness A, Smith G. Antioxidant strategy for cardiovascular disease. The Lancet. 2001;357(9269):1705.

33. Morris M, Tangey C. A Potential Design Flaw of Randomized Trials of Vitamin Supplements. JAMA. 2011;305(13):1348.

34. Kang J. A Randomized Trial of Vitamin E Supplementation and Cognitive Function in Women. Archives of Internal Medicine. 2006;166(22):2462.

35. Niki E, Noguchi N, Tsuchihashi H, Gotoh N. Interaction among vitamin C, vitamin E, and beta-carotene. The American Journal of Clinical Nutrition. 1995;62(6):1322S-1326S.

36. Steinberg D. Low Density Lipoprotein Oxidation and Its Pathobiological Significance. Journal of Biological Chemistry. 1997;272(34):20963-20966.

37. Jiang Q. Natural forms of vitamin E: metabolism, antioxidant, and anti-inflammatory activities and their role in disease prevention and therapy. Free Radical Biology and Medicine. 2014;72:76-90.

38. Letenneur L, Proust-Lima C, Le Gouge A, Dartigues J, Barberger-Gateau P. Flavonoid Intake and Cognitive Decline over a 10-Year Period. American Journal of Epidemiology. 2007;165(12):1364-1371.

39. Hertog M, Feskens E, Kromhout D, Hertog M, Hollman P, Hertog M et al. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. The Lancet. 1993;342(8878):1007-1011.

40. Devore E, Kang J, Breteler M, Grodstein F. Dietary intakes of berries and flavonoids in relation to cognitive decline. Annals of Neurology. 2012;72(1):135-143.

41. Agarwal P, Holland T, Wang Y, Bennett D, Morris M. Association of Strawberries and Anthocyanidin Intake with Alzheimer’s Dementia Risk. Nutrients. 2019;11(12):3060.

42. Root M, Ravine E, Harper A. Flavonol Intake and Cognitive Decline in Middle-Aged Adults. Journal of Medicinal Food. 2015;18(12):1327-1332.

43. Nurk E, Refsum H, Drevon C, Tell G, Nygaard H, Engedal K et al. Intake of Flavonoid-Rich Wine, Tea, and Chocolate by Elderly Men and Women Is Associated with Better Cognitive Test Performance. The Journal of Nutrition. 2008;139(1):120-127.

44. Butchart C, Kyle J, McNeill G, Corley J, Gow A, Starr J et al. Flavonoid intake in relation to cognitive function in later life in the Lothian Birth Cohort 1936. British Journal of Nutrition. 2011;106(1):141-148.

45. Krikorian R, Nash T, Shidler M, Shukitt-Hale B, Joseph J. Concord grape juice supplementation improves memory function in older adults with mild cognitive impairment. British Journal of Nutrition. 2009;103(5):730-734.

46. Krikorian R, Shidler M, Nash T, Kalt W, Vinqvist-Tymchuk M, Shukitt-Hale B et al. Blueberry Supplementation Improves Memory in Older Adults†. Journal of Agricultural and Food Chemistry. 2010;58(7):3996-4000.

47. Whyte A, Williams C. Effects of a single dose of a flavonoid-rich blueberry drink on memory in 8 to 10 y old children. Nutrition. 2015;31(3):531-534.

48. Barfoot K, May G, Lamport D, Ricketts J, Riddell P, Williams C. The effects of acute wild blueberry supplementation on the cognition of 7–10-year-old schoolchildren. European Journal of Nutrition. 2018;58(7):2911-2920.

49. Whyte A, Schafer G, Williams C. The effect of cognitive demand on performance of an executive function task following wild blueberry supplementation in 7 to 10 years old children. Food & Function. 2017;8(11):4129-4138.

50. Whyte A, Cheng N, Butler L, Lamport D, Williams C. Flavonoid-Rich Mixed Berries Maintain and Improve Cognitive Function Over a 6 h Period in Young Healthy Adults. Nutrients. 2019;11(11):2685.

51. Rodriguez-Mateos A, Vauzour D, Krueger C, Shanmuganayagam D, Reed J, Calani L et al. Bioavailability, bioactivity and impact on health of dietary flavonoids and related compounds: an update. Archives of Toxicology. 2014;88(10):1803-1853.

52. Holst B, Williamson G. Nutrients and phytochemicals: from bioavailability to bioefficacy beyond antioxidants. Current Opinion in Biotechnology. 2008;19(2):73-82.

53. Spencer J, Vauzour D, Rendeiro C. Flavonoids and cognition: The molecular mechanisms underlying their behavioural effects. Archives of Biochemistry and Biophysics. 2009;492(1-2):1-9.

54. Spencer J, Vafeiadou K, Williams R, Vauzour D. Neuroinflammation: Modulation by flavonoids and mechanisms of action. Molecular Aspects of Medicine. 2012;33(1):83-97.

55. Williams R, Spencer J. Flavonoids, cognition, and dementia: Actions, mechanisms, and potential therapeutic utility for Alzheimer disease. Free Radical Biology and Medicine. 2012;52(1):35-45.

56. Bell L, Lamport D, Butler L, Williams C. A Review of the Cognitive Effects Observed in Humans Following Acute Supplementation with Flavonoids, and Their Associated Mechanisms of Action. Nutrients. 2015;7(12):10290-10306.

57. Morris M, Jacques P, Rosenberg I, Selhub J. Folate and vitamin B-12 status in relation to anemia, macrocytosis, and cognitive impairment in older Americans in the age of folic acid fortification. The American Journal of Clinical Nutrition. 2007;85(1):193-200.

58. Morris M, Evans D, Schneider J, Tangney C, Bienias J, Aggarwal N. Dietary folate and vitamins B-12 and B-6 not associated with incident Alzheimer’s disease1. Journal of Alzheimer’s Disease. 2006;9(4):435-443.

59. Morris M, Evans D, Bienias J, Tangney C, Hebert L, Scherr P et al. Dietary Folate and Vitamin B12 Intake and Cognitive Decline Among Community-Dwelling Older Persons. Archives of Neurology. 2005;62(4):641.

60. Morris M. Nutritional determinants of cognitive aging and dementia. Proceedings of the Nutrition Society. 2011;71(1):1-13.

61. Morris M, Schneider J, Tangney C. Thoughts on B-vitamins and dementia. Journal of Alzheimer’s Disease. 2006;9(4):429-433.

62. Seshadri S, Beiser A, Selhub J, Jacques P, Rosenberg I, D’Agostino R et al. Plasma Homocysteine as a Risk Factor for Dementia and Alzheimer’s Disease. New England Journal of Medicine. 2002;346(7):476-483.

63. Whalley L, Duthie S, Collins A, Starr J, Deary I, Lemmon H et al. Homocysteine, antioxidant micronutrients and late onset dementia. European Journal of Nutrition. 2013;53(1):277-285.

64. den Heijer T, Vermeer S, Clarke R, Oudkerk M, Koudstaal P, Hofman A et al. Homocysteine and brain atrophy on MRI of non-demented elderly. Brain. 2003;126(1):170-175.

65. Durga J, van Boxtel M, Schouten E, Kok F, Jolles J, Katan M et al. Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial. The Lancet. 2007;369(9557):208-216.

66. Smith A, Smith S, de Jager C, Whitbread P, Johnston C, Agacinski G et al. Homocysteine-Lowering by B Vitamins Slows the Rate of Accelerated Brain Atrophy in Mild Cognitive Impairment: A Randomized Controlled Trial. PLoS ONE. 2010;5(9):e12244.

67. Jager C, Oulhaj A, Jacoby R, Refsum H, Smith A. Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial. International Journal of Geriatric Psychiatry. 2011;27(6):592-600.

68. Oulhaj A, Jernerén F, Refsum H, Smith A, de Jager C. Omega-3 Fatty Acid Status Enhances the Prevention of Cognitive Decline by B Vitamins in Mild Cognitive Impairment. Journal of Alzheimer’s Disease. 2016;50(2):547-557.

69. Savage D, Lindenbaum J. Neurological complications of acquired cobalamin deficiency: clinical aspects. Baillière’s Clinical Haematology. 1995;8(3):657-678.

70. Mandaviya P, Stolk L, Heil S. Homocysteine and DNA methylation: A review of animal and human literature. Molecular Genetics and Metabolism. 2014;113(4):243-252.

71. Devore E, Grodstein F, van Rooij F, Hofman A, Stampfer M, Witteman J et al. Dietary Antioxidants and Long-term Risk of Dementia. Archives of Neurology. 2010;67(7).

72. Chang Y, Chang W, Tsai N, Huang C, Kung C, Su Y et al. The Roles of Biomarkers of Oxidative Stress and Antioxidant in Alzheimer’s Disease: A Systematic Review. BioMed Research International. 2014;2014:1-14.

73. Feart C, Letenneur L, Helmer C, Samieri C, Schalch W, Etheve S et al. Plasma Carotenoids Are Inversely Associated With Dementia Risk in an Elderly French Cohort. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2015;71(5):683-688.

74. Nouchi R, Suiko T, Kimura E, Takenaka H, Murakoshi M, Uchiyama A et al. Effects of Lutein and Astaxanthin Intake on the Improvement of Cognitive Functions among Healthy Adults: A Systematic Review of Randomized Controlled Trials. Nutrients. 2020;12(3):617.

75. Morris M, Tangney C, Wang Y, Sacks F, Bennett D, Aggarwal N. MIND diet associated with reduced incidence of Alzheimer’s disease. Alzheimer’s & Dementia. 2015;11(9):1007-1014.

76. Morris M, Tangney C, Wang Y, Barnes L, Bennett D, Aggarwal N. MIND diet score more predictive than DASH or Mediterranean diet scores. Alzheimer’s & Dementia. 2014;10:P166-P166.